Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector - PubMed (original) (raw)
doi: 10.1038/sj.mt.6300049. Epub 2006 Dec 19.
Affiliations
- PMID: 17180118
- DOI: 10.1038/sj.mt.6300049
Free article
Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector
Dolan Sondhi et al. Mol Ther. 2007 Mar.
Free article
Abstract
Late infantile neuronal ceroid lipofuscinosis (LINCL) is a lysosomal storage disorder caused by mutations in the CLN2 gene and a deficiency of tripeptidyl peptidase I (TPP-I). Prior studies with adeno-associated virus (AAV) serotype 2 or 5 mediated transfer of the CLN2 complementary DNA to the central nervous system (CNS) of CLN2(-/-) mice cleared CNS storage granules, but provided no improvement in the phenotype or survival of this model of LINCL. In this study, AAV serotypes (AAV2, AAV5, AAV8, and AAVrh.10) were compared for the delivery of the same CLN2 expression cassette. AAVrh.10, derived from rhesus macaque, provided the highest TPP-I level and maximum spread beyond the site of injection. The AAVrh.10-based vector functioned equally well in naive rats and in rats previously immunized against human serotypes of AAV. When administered to the CNS of CLN2(-/-) mice, the AAVrh.10CLN2 vector provided widespread TPP-I activity comparable to that in the wild-type mice. Importantly, the AAVrh.10CLN2-treated CLN2(-/-) mice had significant reduction in CNS storage granules and demonstrated improvement in gait, nest-making abilities, seizures, balance beam function, and grip strength, as well as having a survival advantage.
Similar articles
- Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis.
Sondhi D, Peterson DA, Edelstein AM, del Fierro K, Hackett NR, Crystal RG. Sondhi D, et al. Exp Neurol. 2008 Sep;213(1):18-27. doi: 10.1016/j.expneurol.2008.04.022. Epub 2008 Apr 30. Exp Neurol. 2008. PMID: 18639872 Free PMC article. - Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.
Sondhi D, Johnson L, Purpura K, Monette S, Souweidane MM, Kaplitt MG, Kosofsky B, Yohay K, Ballon D, Dyke J, Kaminksy SM, Hackett NR, Crystal RG. Sondhi D, et al. Hum Gene Ther Methods. 2012 Oct;23(5):324-35. doi: 10.1089/hgtb.2012.120. Epub 2012 Nov 6. Hum Gene Ther Methods. 2012. PMID: 23131032 Free PMC article. - AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.
Sondhi D, Peterson DA, Giannaris EL, Sanders CT, Mendez BS, De B, Rostkowski AB, Blanchard B, Bjugstad K, Sladek JR Jr, Redmond DE Jr, Leopold PL, Kaminsky SM, Hackett NR, Crystal RG. Sondhi D, et al. Gene Ther. 2005 Nov;12(22):1618-32. doi: 10.1038/sj.gt.3302549. Gene Ther. 2005. PMID: 16052206 - CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
Kohlschütter A, Schulz A. Kohlschütter A, et al. Pediatr Endocrinol Rev. 2016 Jun;13 Suppl 1:682-8. Pediatr Endocrinol Rev. 2016. PMID: 27491216 Review. - Neural and extraneural expression of the neuronal ceroid lipofuscinoses genes CLN1, CLN2, and CLN3: functional implications for CLN3.
Chattopadhyay S, Pearce DA. Chattopadhyay S, et al. Mol Genet Metab. 2000 Sep-Oct;71(1-2):207-11. doi: 10.1006/mgme.2000.3056. Mol Genet Metab. 2000. PMID: 11001812 Review.
Cited by
- Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside.
Xu L, Yao S, Ding YE, Xie M, Feng D, Sha P, Tan L, Bei F, Yao Y. Xu L, et al. J Transl Med. 2024 Sep 27;22(1):866. doi: 10.1186/s12967-024-05661-2. J Transl Med. 2024. PMID: 39334366 Free PMC article. Review. - Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene.
Sondhi D, Scott EC, Chen A, Hackett NR, Wong AM, Kubiak A, Nelvagal HR, Pearse Y, Cotman SL, Cooper JD, Crystal RG. Sondhi D, et al. Hum Gene Ther. 2014 Mar;25(3):223-39. doi: 10.1089/hum.2012.253. Epub 2014 Mar 4. Hum Gene Ther. 2014. PMID: 24372003 Free PMC article. - Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.
Wolf DA, Lenander AW, Nan Z, Belur LR, Whitley CB, Gupta P, Low WC, McIvor RS. Wolf DA, et al. Neurobiol Dis. 2011 Jul;43(1):123-33. doi: 10.1016/j.nbd.2011.02.015. Epub 2011 Mar 17. Neurobiol Dis. 2011. PMID: 21397026 Free PMC article. - Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia.
Perdomini M, Belbellaa B, Monassier L, Reutenauer L, Messaddeq N, Cartier N, Crystal RG, Aubourg P, Puccio H. Perdomini M, et al. Nat Med. 2014 May;20(5):542-7. doi: 10.1038/nm.3510. Epub 2014 Apr 6. Nat Med. 2014. PMID: 24705334 - When ethics constrains clinical research: trial design of control arms in "greater than minimal risk" pediatric trials.
de Melo-Martín I, Sondhi D, Crystal RG. de Melo-Martín I, et al. Hum Gene Ther. 2011 Sep;22(9):1121-7. doi: 10.1089/hum.2010.230. Epub 2011 May 19. Hum Gene Ther. 2011. PMID: 21446781 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources